EntreMed Inc.
Symbol:
ENMD
Exchange:
Nasdaq
Industry:
Health Care
Products:
Drugs
Company Website: Click Here
Company Info: Click Here
Quote and News: Click Here
Profiled Price:
$0.52
(August 28)
Company Snapshot:
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R)( )in rheumatoid arthritis.
|
